Shares of MannKind Corp. jumped in the days after the biotech company announced its inhalable insulin would be available as an offering with a diabetes testing system sold through Amazon.com Inc. This is good news for the Valencia firm as it has been under threat of delisting from the Nasdaq due to its stock price falling below the $1 minimum price. MannKind announced on May 4 a collaborative deal with digital consumer health company Informed Data Systems Inc., in New York, and its One Drop subscription service and digital health platform for treating diabetes. MannKind will add its Afreeza insulin as an offering through One Drop. One Drop sells its blood glucose monitoring system through Amazon Prime. The system can wirelessly transmit data via Bluetooth to an app on iOS and Android devices. The collaboration with MannKind includes designing a reusable Afreeza inhaler with Bluetooth capabilities. MannKind Chief Commercial Officer Michael Castagna said that conflicting incentives of the U.S. health care system are not aligned to help people with diabetes achieve optimal outcomes. Seven out of 10 people on mealtime insulin are not in the American Diabetes Association goal range of less than 7 percent of hemoglobin A1C cells in a person’s body having glucose attached to them, he added. “Even though injectable insulins have been available for decades, 20 percent of users regularly skip injections,” Castagna said in a prepared statement. “We intend to empower people with diabetes to take charge of their health by trying something different.” The announcement was a big reason for a turnaround in the company’s share price. During the previous quarter’s conference call, Chief Executive Matthew Pfeffer said the company had received a letter from Nasdaq because its stock price had fallen below the exchange’s $1 minimum price. However, the company’s 1-for-5 reverse stock split in March 3 boosted the price to more than $2. “The company has regained compliance with the listing rules and the matter is now closed,” Pfeffer stated in the call. “That issue has now been put to bed following our successful reverse stock split earlier in this year.” But since then, the share price has followed a steadily downward trajectory, and on April 21 fell below the $1 line. That, however, changed with the May 4 announcement of the One Drop deal. The price leapt by 26 percent to close at $1.01 on May 8 and then went up another 43 percent to close May 10 at $1.60. Also on May 10, MannKind reported first quarter results with a net loss of $16.3 million (-17 cents a share) on revenue of $3 million.